Supplementary Materials

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells

Chun-Yu Liu, Pei-Yi Chu, Chun-Teng Huang, Ji-Lin Chen, Hsiu-Ping Yang, Wan-Lun Wang, Ka-Yi Lau, Chia-Han Lee, Tien-Yun Lan, Tzu-Ting Huang, Po-Han Lin, Ming-Shen Dai and Ling-Ming Tseng

Figure S1. Varlitinib suppressed cell viability. MCF 10A, SK-BR-3, MDA-MB-468, HCC1937, HCC70, MDA-MB-231, Hs578T and MDA-MB-453 cells were treated with various concentrations of varlitinib for 72 h and cell viability was measured by MTT assay.

Figure S2. Clinical significance of HER family in TNBC. (A) EGFR, HER2, HER3 and HER4 gene alteration data from The Cancer Genome Atlas (TCGA) database, including copy number variation, mutation and mRNA dysregulation, in patients with breast cancer (left, N = 1098) and TNBC (right, N = 116) was analyzed. (B) Protein phosphorylation levels in TNBC and normal tissues were selected and examined from reverse phase protein arrays (RPPA) data in TCGA database.